APA (7th ed.) Citation

N, B., LK, B., JE, N., V, T., PS, M., V, B., . . . AI, L. (2017). Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins. Cardiology, 138(2), 122. https://doi.org/10.1159/000475460

Chicago Style (17th ed.) Citation

N, Butt, et al. "Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, Prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins." Cardiology 138, no. 2 (2017): 122. https://doi.org/10.1159/000475460.

MLA (9th ed.) Citation

N, Butt, et al. "Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, Prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins." Cardiology, vol. 138, no. 2, 2017, p. 122, https://doi.org/10.1159/000475460.